
Grifols, S.A.
GRFSNASDAQHealthcareDrug Manufacturers - General
Previous close
$8.00
+$0.01 · +0.13%
Pre-market
$7.97
−$0.03 · -0.38%
Aug 24, 4:01 AM ET
GRFS company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Hold
Wait — insufficient conviction to act
Valuation
90
Deep Value
Momentum
32
Weakening
Sentiment
59
Mixed
Risk resilience
57
Elevated Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteGrifols, S.A., a company founded in 1940 and headquartered in Barcelona, Spain, specializes in the development, manufacture, and distribution of therapeutic products, with a primary focus on those derived from human plasma. Its operations are organized into several divisions. The Bioscience division is dedicated to researching, producing, and marketing plasma-derived medicines, such as immunoglobulins, alpha-1 antitrypsin, albumin, and clotting factors, along with other innovative treatments for chronic, rare, prevalent, and life-threatening conditions. The Hospital division provides non-biological pharmaceuticals, medical supplies, clinical nutrition solutions, intravenous therapies, and medical devices. The Diagnostic division develops, manufactures, and commercializes diagnostic products that span the entire healthcare continuum, from prevention and screening to diagnosis, prognosis, and monitoring of diseases and treatments, catering to professional healthcare providers. The Bio Supplies division offers essential biological materials for life-science research, clinical trials, and the manufacturing of pharmaceutical and diagnostic products. These diverse offerings enable healthcare professionals to diagnose and treat patients suffering from conditions like hemophilia, immune deficiencies, and infectious diseases. Grifols serves a wide array of clients, including public and private healthcare organizations, wholesalers, distributors, group purchasing organizations, blood banks, hospitals, and national health systems. The company also maintains a technology collaboration agreement with Mondragon.
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
- Headquarters
- ES
- CEO
- Jose Ignacio Abia Buenache
- Listed since
- Jun 2, 2011
- Employees
- 25,258
Market position
Day range
Current $8.00
52-week range
Current $8.00
- Open
- $8.06
- Previous close
- $7.99
- Volume
- 218.38K
- 0.33× average
- Average volume
- 666.85K
- Average daily volume
- Market cap
- 6.77B USD
- Beta
- 1.19
- Market reference 1
- 50-day average
- $7.5994
- +5.27% above average
- 200-day average
- $8.3215
- -3.86% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- 13.33B EUR
- P/E (TTM)
- 14.7×
- P/B (TTM)
- 1.21×
- P/S (TTM)
- 0.9×
- EV / EBITDA
- 8.21×
- Earnings yield
- 7.13%
- Free cash flow yield
- 13.87%
- Dividend yield
- 0.84%
Profitability & efficiency
- Gross margin
- 37.23%
- Operating margin
- 16.66%
- Net margin
- 6.09%
- Return on equity
- 7.33%
- Return on assets
- 1.96%
- Return on invested capital
- 5.33%
Financial health
- Debt / equity
- 1.54×
- Current ratio
- 2.51×
Earnings
- EPS beat rate
- 18%
- 2 beats, 9 misses, 0 met estimates
- Average EPS surprise
- -22.29%
- 11 comparable reports
- Latest EPS result
- 0.25
- Estimate 0.27 · Miss by 6.96%
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
8 ratingsGRFS peers
ETFs holding GRFS
Funds reporting this stock among their holdings, ordered by reported position size.
iShares Biotechnology ETFIBB13.17M0.12%10.75B USD0.44%$213.56+1.29%
Brandes International ETFBINV7.21M1.33%208.51M USD0.70%$45.66+0.55%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP2.77M0.10%2.71B USD0.20%$69.24+0.92%
Brandes U.S. Small-Mid Cap Value ETFBSMC2.73M1.55%161.61M USD0.70%$40.6728+0.80%
State Street SPDR Portfolio Developed World ex-US ETFSPDW2.44M0.01%41.92B USD0.03%$52.02+0.79%
Capital Group International Core Equity ETFCGIC964.5K0.04%2.48B USD0.54%$37.15+0.95%
ActivePassive International Equity ETFAPIE270.24K0.02%953.79M USD0.45%$39.766+1.16%
Invesco NASDAQ Future Gen 200 ETFQQQS113.95K0.50%22.98M USD0.20%$45.0826+1.10%
iShares Biotechnology ETFIBB- Market value
- 13.17M
- Weight
- 0.12%
- AUM
- 10.75B USD
- Expense ratio
- 0.44%
- Price / 1D
- $213.56+1.29%
Brandes International ETFBINV- Market value
- 7.21M
- Weight
- 1.33%
- AUM
- 208.51M USD
- Expense ratio
- 0.70%
- Price / 1D
- $45.66+0.55%
State Street SPDR S&P Kensho New Economies Composite ETFKOMP- Market value
- 2.77M
- Weight
- 0.10%
- AUM
- 2.71B USD
- Expense ratio
- 0.20%
- Price / 1D
- $69.24+0.92%
Brandes U.S. Small-Mid Cap Value ETFBSMC- Market value
- 2.73M
- Weight
- 1.55%
- AUM
- 161.61M USD
- Expense ratio
- 0.70%
- Price / 1D
- $40.6728+0.80%
State Street SPDR Portfolio Developed World ex-US ETFSPDW- Market value
- 2.44M
- Weight
- 0.01%
- AUM
- 41.92B USD
- Expense ratio
- 0.03%
- Price / 1D
- $52.02+0.79%
Capital Group International Core Equity ETFCGIC- Market value
- 964.5K
- Weight
- 0.04%
- AUM
- 2.48B USD
- Expense ratio
- 0.54%
- Price / 1D
- $37.15+0.95%
ActivePassive International Equity ETFAPIE- Market value
- 270.24K
- Weight
- 0.02%
- AUM
- 953.79M USD
- Expense ratio
- 0.45%
- Price / 1D
- $39.766+1.16%
Invesco NASDAQ Future Gen 200 ETFQQQS- Market value
- 113.95K
- Weight
- 0.50%
- AUM
- 22.98M USD
- Expense ratio
- 0.20%
- Price / 1D
- $45.0826+1.10%
Continue in GoAI
Research GRFSresearch.disclaimer





